Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Acquisition Strategy Differentiates Company in Projected $51B Global Cannabis Market
08 Sep 2023
Acquisition
Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Acquisition Strategy Differentiates Company in Projected $51B Global Cannabis Market
NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- via IBN — Lucy Scientific Discovery Inc. (NASDAQ: LSDI) today announces its placement in an editorial published by FinancialNewsMedia ("FNM") a multifaceted financial publishing company for public entities.
To view the full publication, “With Increasing Legal Acceptance Global Cannabis Market Projected to Reach $51 Billion in 2023,” please visit: https://IBN.fm/1lmO3
“The global cannabis market just continues to keep growing year after year. The increasing legalization of cannabis and rising acceptance of its use for medical purposes are the key factors driving the growth of the market. A report from Statista projected that revenue in the global cannabis market is projected to reach US$51.27 billion in 2023; revenue is expected to show an annual growth rate (CAGR 2023–2028) of 14.95%, resulting in a market volume of US$102.90 billion by 2028. . . . “
“The report said: ‘. . . The cannabis market can be considered from three different application perspectives, “spiritual purpose,” “health condition management,” and “wellness management.” The recreational cannabis market includes the consumption of cannabis for nonmedicinal reasons, such as boosting physical performance, pursuing creative activities, and experiencing spirituality. Recreational cannabis can be consumed in the form of extracts, dried cannabis, edibles and beverages. Active cannabis companies in the markets this week include: Lucy Scientific Discovery Inc. (LSDI).”
Lucy Scientific Discovery is a NASDAQ company with holdings and operations in a variety of psychotropic businesses. The company holds a Controlled Drugs and Substances Dealer’s License granted by Health Canada’s Office of Controlled Substances. Lucy Scientific Discovery Inc. and its wholly owned subsidiary, LSDI Manufacturing Inc., operate under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada). This specialized license authorizes LSDI to develop, sell, deliver and manufacture pharmaceutical-grade active pharmaceutical ingredients (“APIs”) used in controlled substances and their raw material precursors. With a focus on pioneering innovative therapies for patients in need, Lucy Scientific Discovery Inc. is dedicated to advancing the understanding and applications of psychotropic medicines, improving mental health outcomes, and enhancing well-being for individuals worldwide.
For more information, visit the company’s website at www.LucyScientific.com
NOTE TO INVESTORS: The latest news and updates relating to LSDI are available in the company’s newsroom at https://ibn.fm/LSDI
About IBN
IBN (InvestorBrandNetwork) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire (IW) to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness.
IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Corporate Communications:
IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
IBN is unlike anything you’ve seen before…
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.